General description

According to the World Health Organization classification system, the major diagnostic criterion for bone marrow involvement by Systemic Mastocytosis (SM) is the presence of dense aggregates (>15 cells) of mast cells. Expression of CD25, a low-affinity receptor for interleukin-2 (IL-2), is a reliable diagnostic tool for distinguishing neoplastic mast cell aggregates from reactive proliferations, and has therefore recently become a minor criterion for the diagnosis of SM. Hahn et al. demonstrated that aberrant staining of Mast cell clusters by anti-CD25 antibody in GI biopsies was essentially diagnostic of SM. Anti-CD25 antibody has also been useful in identifying mast cells in skin biopsies in the setting of Urticaria Pigmentosa, which is predictive of Systemic Mastocytosis. Quantitation of regulatory T cells (Treg) in the setting of hepatocellular carcinoma has been used as an independent predictive factor of tumor recurrence after hepatic resection for HCC. Also, the percentage of tumor-infiltrating CD25+FOXP3+ regulatory T cells among tumor cells, inside tumor parenchyma and at its periphery, is significantly higher in recurrent cutaneous melanoma than in non-recurrent melanoma.

Legal Information

Cell Marque is a trademark of Sigma-Aldrich Co. LLC

Linkage

CD25 Positive Control Slides, Product No. 125S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

Other Notes

For Technical Service please contact: 800-665-7284 or email: [email protected]

Physical form

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and ﹤0.1% Sodium Azide

Preparation Note

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

Quality